2. Search Result
Search Result
Results for "

selective inhibition

" in MedChemExpress (MCE) Product Catalog:

436

Inhibitors & Agonists

4

Screening Libraries

6

Peptides

1

Inhibitory Antibodies

26

Natural
Products

14

Isotope-Labeled Compounds

4

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15546
    BMS-817399

    		CCR Inflammation/Immunology
    BMS-817399 is a potent, selective, and orally bioavailable CCR1 antagonist. BMS-817399 exhibits CCR1 binding affinity and chemotaxis inhibition potencies of 1 and 6 nM (IC50), respectively. BMS-817399 can be used for the research of rheumatoid arthritis .
    BMS-817399
  • HY-N1377
    Nevadensin

    		Carboxylesterase Bacterial Infection Metabolic Disease Inflammation/Immunology
    Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1 (hCE1) with an IC50 of 2.64 μM. Nevadensin has a variety of pharmacological effects such as anti-mycobacterium tuberculosis activities, antitussive, anti-inflammatory and anti-hypertensive .
    Nevadensin
  • HY-12960
    SKLB4771

    FLT3-​IN-​1

    		 FLT3 c-Kit Apoptosis Cancer
    SKLB4771 is a potent and selective Flt3 inhibitor with an IC50 value of 10 nM. SKLB4771 downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue .
    SKLB4771
  • HY-125629
    Primordazine B

    		Others Others
    Primordazine B is a small molecule compound identified by chemical screening in zebrafish embryos with the activity of selectively destroying Primordial Germ Cells (PGCs). Primordazine B inhibits a process called Poly(A)-tail Independent Non-canonical Translation (PAINT) without inhibition of polyadenylate tail dependent typical translation (PAT). Primordazine B can be used to study translational control of cells in specific physiological or pathological states, such as gene expression regulation during cell dormancy, viral infection, or stress conditions .
    Primordazine B
  • HY-147984
    hCAXII-IN-3

    		Carbonic Anhydrase Cancer
    hCAXII-IN-3 (Compound 6o) is a selective human carbonic anhydrase XII (hCAXII) inhibitor with a Ki of 10.0 nM .
    hCAXII-IN-3
  • HY-147985
    hCA I-IN-1

    		Carbonic Anhydrase Cancer
    hCA I-IN-1 (Compound 6q) is a human carbonic anhydrase I (hCA I) inhibitor with Ki values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .
    hCA I-IN-1
  • HY-147986
    hCA I-IN-2

    		Carbonic Anhydrase Cancer
    hCA I-IN-2 (Compound 6d) is a selective human carbonic anhydrase I (hCA I) inhibitor with Ki values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .
    hCA I-IN-2
  • HY-N1377R
    Nevadensin (Standard)

    		Carboxylesterase Bacterial Infection Metabolic Disease Inflammation/Immunology
    Nevadensin (Standard) is the analytical standard of Nevadensin. This product is intended for research and analytical applications. Nevadensin is a naturally occurring selective inhibitor of human carboxylesterase 1 (hCE1) with an IC50 of 2.64 μM. Nevadensin has a variety of pharmacological effects such as anti-mycobacterium tuberculosis activities, antitussive, anti-inflammatory and anti-hypertensive .
    Nevadensin (Standard)
  • HY-143465
    BChE-IN-5

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-5 is a potent and selective BChE inhibitor of hBChE over hAChE with an IC50 of 2.8 nM for BChE. BChE-IN-5 has the potential for the research of alzheimer’s disease .
    BChE-IN-5
  • HY-N3614
    Confluentic acid

    		Others Others
    Confluentic acid exhibits selective inhibition of Monoamine oxidase B, demonstrating an IC50 value of 0.22 micromolar.
    Confluentic acid
  • HY-134904
    RMC-6272
    1 Publications Verification

    RM-006

    		 mTOR Cancer
    RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors .
    RMC-6272
  • HY-129496
    NP-313

    		Thrombin Cardiovascular Disease
    NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca 2+ inward flow .
    NP-313
  • HY-12900
    RB-005

    		SphK Inflammation/Immunology Cancer
    RB-005 is a selective inhibitor of sphingosine kinase 1 (SK1) (IC50=3.6 µM), with weaker inhibition of another isoenzyme, SK2. The selective inhibition of RB-005 helps to distinguish the biological functions and roles of SK1 and SK2, which can be used in the study of inflammatory diseases and cancer .
    RB-005
  • HY-139001
    JKE-1716

    		Glutathione Peroxidase Ferroptosis Others
    JKE-1716 is a potent and selective nitrolic acid-containing GPX4 inhibitor. JKE-1716 is able of inducing ferroptosis selectively through covalent GPX4 inhibition .
    JKE-1716
  • HY-130199
    Psoromic acid

    Parellic acid

    		 Others Metabolic Disease
    Psoromic acid is a potent and selective RabGGTase (Rab geranylgeranyl transferase) inhibitor with an IC50 value of 1.3 µM. Psoromic acid is an antioxidative agent. Psoromic acid exhibits a competitive type of HMGR inhibition and mixed type of ACE (angiotensin converting enzyme) inhibition .
    Psoromic acid
  • HY-106951
    MK 386

    L-733692

    		 5 alpha Reductase Cancer
    MK 386 (L-733692) is a selective 5-α-reductase I inhibitor, used for prostate cancer inhibition .
    MK 386
  • HY-N12747
    Dichlorogelignate

    		Topoisomerase Others
    Dichlorogelignate (compound 4) is a selective inhibitor of topoisomerase II (Topo II). Dichlorogelignate has 100% inhibition at 50 μM .
    Dichlorogelignate
  • HY-101578
    2614W94

    		Monoamine Oxidase Neurological Disease
    2614W94 is a selective, reversible inhibitor of monoamine oxidase-A with a competitive mechanism of inhibition and IC50 of 5 nM and Ki of 1.6 nM with serotonin as substrate.
    2614W94
  • HY-15979A
    H-89 dihydrochloride
    Maximum Cited Publications
    117 Publications Verification

    		 PKA Autophagy Others
    H-89 dihydrochloride is a potent and selective inhibitor of protein kinase A (PKA) with an IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase.
    H-89 dihydrochloride
  • HY-12528
    DBPR108

    		Dipeptidyl Peptidase Metabolic Disease
    DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9.
    DBPR108
  • HY-112082
    BAY885

    		ERK Cancer
    BAY885 is a highly potent and selective ERK5 inhibitor with an IC50 of 35 nM. BAY885 shows weak inhibition on others kinases .
    BAY885
  • HY-139852
    PLAP-IN-1

    		Phosphatase Cancer
    PLAP-IN-1 is a potent (IC50 = 32 nM) and selective PLAP inhibitor, with no detectable inhibition of tissue non-specific alkaline phosphatase (TNAP) activity.
    PLAP-IN-1
  • HY-14719
    RO4987655
    5 Publications Verification

    CH4987655

    		 MEK Cancer
    RO4987655 is an orally active and highly selective MEK inhibitor with an IC50 of 5.2 nM for inhibition of MEK1/MEK2.
    RO4987655
  • HY-157889
    ZINC000028464438

    		HDAC Cancer
    ZINC000028464438 is a selective HDAC11 inhibitor with an IC50 of 3.5 µM. ZINC000028464438 shows almost no inhibition for other HDAC subtypes .
    ZINC000028464438
  • HY-153398
    Enpp-1-IN-17

    		Phosphodiesterase (PDE) Infection Cancer
    Enpp-1-IN-17 (example 274) is a potent ENPP1 inhibitor, with the inhibition constants (Ki values) toward cGAMP and ATP hydrolysis of 100 nM-1 μM and > 1 μM, respectively. The selectivity ratio for inhibition of cGAMP hydrolysis versus ATP hydrolysis is >6.4 .
    Enpp-1-IN-17
  • HY-104013
    Aminopurvalanol A
    1 Publications Verification

    		 CDK Apoptosis Cancer
    Aminopurvalanol A is a potent, selective, and cell permeable inhibitor of Cyclins/Cdk complexes. Aminopurvalanol A preferentially targets the G2/M-phase transition inhibiting cancer cell differentiation. Aminopurvalanol A causes the inhibition of sperm fertilizing ability via the inhibition of physiological capacitation-dependent actin polymerization .
    Aminopurvalanol A
  • HY-15418
    RS 504393
    15+ Cited Publications

    		 CCR Inflammation/Immunology Endocrinology
    RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 89 nM and > 100 μM for inhibition of human recombinant CCR2 and CCR1 receptors respectively).
    RS 504393
  • HY-15663
    IPA-3
    10+ Cited Publications

    		 PAK Cancer
    IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, and shows no inhibition to group II PAKs (PAKs 4-6).
    IPA-3
  • HY-12089
    Torcetrapib

    CP-529414

    		 CETP Endocrinology
    Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM .
    Torcetrapib
  • HY-N3035
    Tetrahydroepiberberine

    		Fungal Influenza Virus Infection
    Tetrahydroepiberberine is a isoquinoline alkaloid isolated from Corydalis impatiens (Pall). Tetrahydroepiberberine has antifungal and selective inhibition against the PI-3 virus activities .
    Tetrahydroepiberberine
  • HY-144706
    Axl-IN-3

    		TAM Receptor Cancer
    Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC50 of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases .
    Axl-IN-3
  • HY-147655
    CQ211

    		Others Cancer
    CQ211 is a potent and selective RIOK2 inhibitor with a Kd of 6.1 nM. CQ211 exhibits potent proliferation inhibition activity against multiple cancer cell lines .
    CQ211
  • HY-108530
    MM11253

    		RAR/RXR Cancer
    MM11253 is a potent and selective RARγ antagonist with an IC50 of 44 nM. MM11253 has lower inhibition of RARα, RARβ and RXRα. MM11253 blocks the growth inhibitory effects of RARγ-selective agonists .
    MM11253
  • HY-19972
    ML243

    		Others Cancer
    ML243 is a selective small-molecule inhibitor of breast cancer stem cells. ML243 has 32-fold greater selective inhibition in the breast CSC-like cell line HMLE_shECad than the control cell line HMLE_shGFP .
    ML243
  • HY-162257
    BTK-IN-34

    		Btk Cancer
    BTK-IN-34 (compound 9h) is a selective BTK inhibitor. BTK-IN-34 shows antiproliferative activity in RAMOS cells through selective inhibition of pBTK (Tyr223) without affecting Lyn and Syk, upstream proteins in the BCR signaling pathway .
    BTK-IN-34
  • HY-115908
    ZDLD13

    		CDK Apoptosis Cancer
    ZDLD13, a β-carboline, is an orally active and selective CDK4/CycD3 inhibitor with an IC50 value of 0.38 μM. ZDLD13 exhibits potent anti-HCT116 activity including inhibition of colony formation, inhibition of invasion and migration, inducing of apoptosis, and arresting of G1 phase in cell cycle. ZDLD13 shows significant tumor growth inhibition in HCT116 tumor xenograft model .
    ZDLD13
  • HY-119288
    BC-23

    NSC 45382

    		 Proteasome Cancer
    BC-23 (NSC 45382) is a proteasome inhibitor. BC-23 exhibits good inhibition of CT-L activity of the proteasome and is selective for malignant over normal cells .
    BC-23
  • HY-116482
    Desmedipham

    		Others Others
    Desmedipham is a selective systemic phenyl-carbamate herbicide. Desmedipham acts by disrupting CO2 fixation and the production of intermediary energy components-ATP and NADPH2 and inhibition of Hill reaction .
    Desmedipham
  • HY-147664
    hCAXII-IN-1

    		Carbonic Anhydrase Cancer
    These compounds show selective inhibition on tumor related subtypes HCA IX and XII, and are also considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.
    hCAXII-IN-1
  • HY-150095
    YE6144

    		Others Inflammation/Immunology
    YE6144 is a prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 selectively suppresses IRF5 activity through inhibition of IRF5 phosphorylation .
    YE6144
  • HY-119649
    Flonicamid

    IKI220

    		 Parasite Infection
    Flonicamid (IKI220) is a novel systemic insecticide with selective activity against hemipterous pests. The main insecticidal mechanism of flonicamid is starvation based on the inhibition of stylet penetration to plant tissues .
    Flonicamid
  • HY-131922
    Iso-OMPA

    Tetraisopropyl pyrophosphoramide

    		 Cholinesterase (ChE) Neurological Disease
    Iso-OMPA (Tetraisopropyl pyrophosphoramide) is a selective inhibitor of the irreversible butyrylcholinesterase (BuChE). Iso-OMPA enhances soman toxicity in rats associated with the inhibition of plasma carboxylesterase (CarbE) .
    Iso-OMPA
  • HY-162100
    MR-2088

    		ULK Autophagy Cancer
    MR-2088 is a selective ULK1/ULK2 inhibitor with pEC50 values of 8.3 and 8.7, respectively. MR-2088 selectively inhibits autophagy through ULK1/2 mediated inhibition .
    MR-2088
  • HY-139664
    GSK-3685032
    5 Publications Verification

    		 DNA Methyltransferase Cancer
    GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition .
    GSK-3685032
  • HY-145072
    BSJ-01-175

    		CDK Cancer
    BSJ-01-175 is a potent and selective CDK12/13 covalent inhibitor. BSJ-01-175 demonstrates exquisite selectivity, potent inhibition of RNA polymerase II phosphorylation, and downregulation of CDK12-targeted genes in cancer cells .
    BSJ-01-175
  • HY-15979
    H-89
    Maximum Cited Publications
    117 Publications Verification

    		 PKA Autophagy Neurological Disease
    H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.
    H-89
  • HY-108488
    KB SRC 4

    		Src Cancer
    KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.
    KB SRC 4
  • HY-132808
    Atuzabrutinib

    SAR 444727; PRN473

    		 Btk Inflammation/Immunology
    Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling .
    Atuzabrutinib
  • HY-157135
    hCAIX-IN-19

    		Carbonic Anhydrase Cancer
    hCAIX-IN-19 is a sulfonamides inhibitor against hCA IX with an inhibition constant (KI ) of 6.2 nM and show good selectivity over hCA I (hCA I/ hCA IX = 117) .
    hCAIX-IN-19
  • HY-144687
    ATM Inhibitor-4

    		ATM/ATR PI3K mTOR Cancer
    ATM Inhibitor-4 (compound 39) is a potent and selective ATM inhibitor, with an IC50 of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability .
    ATM Inhibitor-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: